SS Innovations is no longer a brochure robotics story. The SSi Mantra is being installed, used, and paid for in India at a pace that makes the company a genuine commercial vendor rather than a concept. What changed this year is not the existence of demand. It is the collision between that demand and a balance sheet that still cannot fund the next twelve months of expansion, regulatory work, and working capital without new equity. Mid-year sales in the June quarter reached $14 million. That print is the proof of adoption and the start of the funding argument, not the end of it.
The tension sits in mix and cash conversion. Hospitals still buy systems on deferred schedules that stretch several years, so reported sales outrun cash. Instruments and warranty, the recurring layer that turns a robot into an annuity, remain a thin slice of the first-half book. Meanwhile research spending jumped as the company pushed a Food and Drug Administration filing and a European CE mark process that has already slipped once. Gross margin in the June quarter sat near fifty-one percent, below last year's comparison. The India factory can make a cheaper robot. It has not yet made a self-funding one.
Cumulative procedures and the installed base kept climbing after quarter-end, and long-distance telesurgery cases from Australia, Guyana, and Colombia keep the brand in surgical journals. Those events do not pay the overdraft or retire the going-concern paragraph. Cash excluding restricted deposits was $14 million. The overdraft line exceeded that cash pile. The open question for the next several quarters is whether instrument attach and India utilization thicken cash flow enough to shrink the at-the-market facility, or whether Western clearance stays the only story the multiple is willing to underwrite.